The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Updated analysis from MOUNTAINEER: tucatinib and trastuzumab for HER2-positive mCRC
John Strickler, MD, Duke Cancer Center, Durham, NC, presents additional analyses of MOUNTAINEER (NCT03043313), a Phase II study of tucatinib and trastuzumab for HER2-positive metastatic colorectal cancer (mCRC). Tucatinib monotherapy and tucatinib with trastuzumab after crossover were well tolerated, consistent with the primary analysis, with 18% of patients who crossed over achieving a response. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
